# Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma

> **NCT00999830** · PHASE2 · COMPLETED · sponsor: **Innate Pharma** · enrollment: 27 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** IPH2101

## Key facts

- **NCT ID:** NCT00999830
- **Lead sponsor:** Innate Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2012-06
- **Final completion:** 2013-06
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2016-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00999830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00999830, "Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00999830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*